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r he IPTS Report was launched in December 1995, on the request and under the auspices of Commissioner Cresson. What seemed like a daunting challenge in kite 1995, now appears in retrospect 
as a crucial galvaniser of the IPTS' energies and skills. 
The Report has published articles in numerous areas, maintaining a rough balance between them, and 
exploiting mterdisciplinarity as far as possible. Articles are deemed prospectively relevant if they attempi to 
explore issues not yet on the policymaker's agenda (but projected to be there sooner or later), or 
underappreciated aspects of issues already on the policymaker's agenda. The long drafting and redrafting 
process, based on a series of interactive consultations with outside experts, guarantees quality control. 
The clearest indication of the report's success is that it is being read. An initial print run of 2000 for the first 
issue (00) in December 1995 looked optimistic at the time, but issue 00 has since turned into a collector's 
item. Total readership rose to around 10,000 iti 1997, with readers continuing to be drawn from a variety 
of backgrounds and regions world-wide, and in 1998 a shift in emphasis towards the electronic version on 
the Web has begun. 
The laurels the publication is reaping are rendering it attractive for authors from outside the Commission. 
We have already published contributions by authors from such renowned institutions as the Dutch TNO, lhe 
German VDI, the Italian ENEA and the US Council of Strategic and International Studies. 
Moreover, the ¡PTS formally collaborates on the production of the IPIS Report with a group of prestigious 
European institutions, with whom the IPTS has formed the European Science and Technology Observatory 
(ESTO), an important part of the remit of the IPTS. The IPTS Report is the most visible manifestation of this 
collaboration. 
The Report is produced simultaneously in four languages (English, French, German and Spanish) by the 
IPTS; to these one could add the Italian translation volunteered by ENEA: yet another sign of the Report's 
increasijig visibility. The fact that it is not only available in several languages, but also largely prepared and 
produced on the Internet World Wide Web, makes it quite an uncommon undertaking. 
We shall continue to endeavour to find the best way of fulfilling the expectations of our quite diverse 
readership, avoiding oversimplification, as well as encyclopaedic reviews and the inaccessibility of academic 
journals. The key is to remind ourselves, as well as the readers, that we cannot be all things to all people, 
that it is important to carve out our niche and continue opti?}ially exploring and exploiting il, hoping lo 
illuminate topics under a new, revealing light for the benefit of the readers, in order to prepare them for 
managing the challenges ahead. 
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Preface 
Α/Ύ ith the launching of the firàt call for tender for participation 
wr the EU Fifth Framework Programme for R&D is fully 
under way. The Programme emphasized science and technology which 
supports the European Union and its policies. It promotes scientific 
and technological excellence, addresses socio-economic and competitive 
needs, and attaches partœular importance to the use and exploitation 
of R&D results. The accumulated experience from previous 
programmes has given the Fifth Framework Programme the means 
and preparedness to react promptly to scientific and technological 
challenges which may arise and directly or indirectly affect the EU. 
In terms of structure, as many readers may already know, the Fifth 
Framework Programme has been simplified and is built on four 
thematic programmes: the Quality of Life, the Information Society, 
Competitive and Sustainable Growth, and Energy and Environment. 
These are complemented by three horizontal programmes on the 
International role of European Research, on Innovation and SMEs, 
and on Human Potential. 
These programmes will be implemented through a series of actions 
ranging from shared cost actions between the Commission and 
participating consortia, to the R&D fellowships, named after the 
scientist Marie Curie. Concerted actions, thematic networks, together 
with the necessary accompanying measures, will also be financed. 
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The first call for tender has ushered the Fifth Framework 
Programme in. From this point on, and until the end of the 
programme, annual, joint, dedicated and permanently open calls will 
co-exist to provide potential participants with a range of 
opportunities in which to take part. 
The Commission has set the course for a sound EU R&D programme 
and has started the process. Now is the opportunity for researchers to 
define and submit proposals that will give it substance and 
momentum, in order to realize the potential benefits which R&D holds 
for the EU. 
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4 Editorial 
Innovation and Technology Policy 
The impact of Wind energy policy on innovation 
A number of EU countries have witnessed considerable growth in the use of wind power. 
Useful lessons can be learned for application to other environ-mental technologies. 
13 Thinking about E M U and science 
European monetary union is predicted to have wide-reaching effects on the process of 
European integration. One area that little attention has been paid to is how it might 
affect European research. 
Methods 
18 The Consumer Product Safety Database: products, risks and expertise 
The European Commission is putting in place the tools to ensure consumer safety in 
the single market. In this context a database is being created by the JRC to meet the 
need for a point of reference for expertise on product safety. 
Biotechnology 
27 Patent protection for blotechnologlcal inventions: incentive for 
European biotech Innovators 
The debate surrounding the patenting of biological material is far from over. As the 
directive passes into law at Member State level, it remains to be seen to what extent it 
will achieve all its goals, including providing the biotech industry the framework it 
needs in which to grow. 
34 Transatlantic investments and human capital formation: the case of 
_ biotech firms 
An investigation of knowledge flows in the biotechnology sector between Europe and 
the US shows the European industry to be active in forming alliances with US 
companies, with a view to acquiring both know-how and finance. 
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E D I T O R I A L 
Dimi t r is Kyriakou 
C ompetitiveness is one of the foggiest concepts to define. It has been used in ways that range from making it effectively synonymous to profitability, to market 
share, to trade surpluses, to high-value-added 
exports, to high wages, etc. The above, although 
potentially useful indicators in individual 
contexts, do not suffice for a coherent notion. 
It has been correctly pointed out that whereas 
firms clearly compete in the marketplace, nations 
(excluding military conflict) do not compete in the 
same way. Nations do not have balance sheets, no 
identifiable product, or customers. Moreover 
quite unlike what happens between competing 
firms selling the same product, the good fortune of 
your neighbour/rival may be good news for you, 
to the extent that your neighbour is likely to 
spend at least a small part of their extra income 
on imports. 
Yet competitiveness reduced to ability of 
easily recognisable firms to capture profits and 
market shares does not satisfactorily capture the 
whole story. Competitiveness has to include a 
forward-looking dimension. It would be trivial 
for firms to sell at rock-bottom prices in order to 
enlarge their market shares. But how long can 
they go on doing that if profits are negative? Or 
if they are positive but not enough for the 
investment necessary to keep up with the 
competition? Firms could also boost profits by 
underpaying their workers. How long however 
would they remain profitable when the 
increasingly critical skilled staff will defect to 
other jobs (and in any case will have little 
incentive to upgrade skills and considerable 
incentive to strike)? 
Competitiveness, moreover, should extend to 
all levels, not just the larger firms but also the 
small ones and even individual economic 
agents. At the macro-level the forward-looking 
character of any definition of competitiveness 
must include characteristics of the social whole 
that would allow society to function fruitfully 
and harmoniously. 
Competitiveness is then a measure of a 
society's ability to allow economic entities of all 
sizes, to accumulate increasingly coveted skills, 
capacities and products which are differentiated, 
hard to reverse-engineer, and are handsomely 
rewarded. The key to success in this sense is the 
ability to attract the capital (human and 
otherwise) to generate and nurture economic 
entities which can compete successfully 
worldwide on a social fabric which can absorb 
©IPTS-JRC-Seville, 1999 
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the social tensions bound to emerge as demands 
shifts, skills need updating and adjustment is 
often inevitable. 
5 
attractive societies, in terms of social peace, 
natural environment, open democratic political 
practices, low crime rates, etc. 
Note that in this formulation the role of 
the social fabric is crucial. Unlike older 
formulations competitiveness is not sacrificed in 
order to reduce social tensions. Rather 
competitiveness in the longer run needs social 
environments which can draw capital - the old-
fashioned type, as well as the increasingly more 
important human type - through the creation of 
To put it in a nutshell: competitiveness marks 
societies which generate and nurture economic 
entities (from individual to large firms) which 
can flourish and perform successfully in world 
markets, and to which human (and other 
forms of) capital is attracted. Competitiveness 
implies attractive societies in which to live, work 
and invest. 
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Over the past 20 years 
the focus has been on 
end-of-pipe 
technologies to meet 
environmental 
demands rapidly and 
without fundamental 
changes in technology 
and skills 
The impact of Wind energy policy 
on innovation 
Jens Hemmelskamp, IPTS, and Olav Hohmeyer, University of Flensburg 
Issue: Some countries of the EU have witnessed an amazing surge In the development of 
wind power generation over recent years. National governments, through their 
environmental policy, are playing a crucial role In influencing the development of 
wind energy. 
Relevance: The significance of the Influence of environmental policy on innovation has 
not yet been properly appreciated in the scientific debate, environmental policy tending 
to be regarded as just one more decision-making parameter for innovation-related 
decisions by the companies involved, consequently, the relationship between these 
environmental policy instruments and innovation behaviour in the renewable energy 
technology field must be analysed In the context of numerous economic, social, legal 
and technological factors. The main question now is what we can learn from these 
cases for the design of an innovation-friendly regulatory regime of environmental 
policy approaches. 
introduction 
S ustainable development demands the long-term availability of natural resources and preservation of environmental quality. Thus, it requires changes in existing 
production methods and consumer behaviour. 
The political and scientific debate has stressed 
above all the importance of progress 
in environmental technology with respect 
to exploiting resources, production, consumption 
and disposal. 
During the past 20 years, innovation 
has primarily focused on end-of-pipe 
technologies, and this has already resulted in 
considerable reductions in environmental 
pressure. However, the demanding criteria for 
sustainable development cannot be met by this 
approach alone. In the future it will therefore be 
crucial to work towards additional fundamental 
technological change and to shift the direction 
taken by progress up to now, through the 
development and application of new, 
sustainable manufacturing techniques and 
products, and so bring about a shift from end-of-
pipe to embedded environmental protection. 
Thus, policy makers are now faced with the 
question as to what environmental policy 
measures are most the appropriate way to bring 
about this shift in private-sector innovation 
towards more environmental innovation. 
Support for wind energy offers a good 
example of innovation-oriented environmental 
policy. Since 1989, with the help of various 
©IPTS-JRC -Seville, 1999 
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environmental policy measures, wind generation 
capacity of more than 2,800 Megawatts has been 
installed in Germany and the wind-generated 
electricity component of net electricity 
consumption in Schleswig-Holstein has reached 
over 12% and in Lower Saxony about 6%. 
Considerable capacity growth can also be seen in 
Denmark and Great Britain as the outcome of 
environmental policy measures. 
Considerable progress in technological 
development 
Up until the 1970s, R&D activity in the use of 
wind energy was directed at meeting the 
requirements of centralized electricity supply by 
large power stations with increasingly high 
performance and falling power generation costs. 
These attempts failed, however, as it proved 
impossible at that time to build large wind power 
plants or to integrate small wind farms into the 
central supply structure. 
Only after the energy crises of the 1970s there 
was a change in attitude and changes in energy 
law and investment subsidies for the use of wind 
energy were introduced. In the beginning, 
different technical concepts were pursued, based 
on systems with one, two or three rotor blades. 
Most wind generators today have three blades. 
While in 1989, the available equipment 
generated less than 150 kW, today's commercially 
available models can generate over 1.5 MW. The 
diameter of the rotors has increased from an 
average 30m to a scale of up to 65m, towers have 
grown from 30m to 98m (see Figure 1). 
Figure 1. 
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Two designs are now emerging as dominant: in 
smaller models, a three-phase generator powered 
by a turbine with fixed rotational speed is coupled 
to a main circuit. The rotor blades are fixed to the 
hub and their pitch cannot be altered. Power 
generation is controlled by a cut-out, which is 
activated when a particular wind speed is 
reached. This technology has the advantage of 
low manufacturing and maintenance costs. 
Larger wind farms appear to be settling for 
technologically more complex configurations 
where the pitch of the rotor blades can be adjusted 
Support for wind 
energy offers a 
good example of 
innovation-oriented 
environmental policy 
The energy crises of 
the 1970s created the 
change in attitudes 
necessary for the 
framework to be 
modified so as to allow 
the decentralized 
approach needed for 
wind power 
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Two designs now 
dominate: a simpler 
arrangement for 
smaller wind farms and 
a more complex and 
more flexible design 
for larger ones 
Although wind 
generators will 
continue to 
be improved, 
fundamental 
changes in design 
are unlikely 
Developing and 
introducing integrated 
technologies is slower 
to achieve than is the 
case for end-of-pipe 
technologies 
In Denmark a 
combination of various 
policy instruments has 
proved successful in 
creating a market for 
wind power technology 
and an industry 
to serve it 
and the rotational speed is variable. This system 
makes it possible to compensate for short-term 
changes in load or fluctuations in power, and 
thereby optimizes the plant's suitability for grid-
connected operation. Another trend can be seen 
in large wind turbines towards a gearless cord 
system with multi-polar generators. 
In the future, less fundamental technological 
change can be expected, and rather more 
incremental improvements aimed at extending 
product life, improving efficiency and the quality 
of the electricity generated, at reducing operating 
noise, and at improved performance under highly 
corrosive offshore conditions. Opinion is divided 
as to further developments of scale. On the one 
hand it is argued that the best ratio of costs to 
performance has already been exceeded in 
1.5 MW equipment, while others argue that, 
particularly with respect to exploiting offshore 
locations, further growth up to and over 2 MW 
can be expected. Manufacturing processes should 
become more automated and manufacturers will 
produce in larger batches. 
Different policy approaches in Denmark, 
the UK and Germany 
Environmental policy is often short-term 
oriented. As a consequence, there is a tendency 
for minor technical improvements relying mainly 
on end-of-pipe technologies in order to meet 
emissions reduction requirements as quickly as 
possible whilst continuing to use existing 
technologies and available expertise. In contrast, 
the development and introduction of clean and 
integrated technologies needs more time and is 
rarely turned into a practical reality. However, the 
definition of a reliable environmental policy 
framework could give important incentives for the 
development of preventive environmental 
protection technologies and the creation of a pool 
of environmental technology solutions for the 
reduction or avoidance of environmental 
stress. Solutions could then be drawn from this 
pool at a later date. 
In Denmark, such a policy approach 
supporting the development and launch of 
environmentally friendly technologies has been a 
- successful - reality in the wind energy sector 
since the 1970s. Supported by a combination of 
various policy instruments, especially subsidies, 
Danish policy first created a technological niche, 
and then a market niche, for wind technology, 
one which has since developed into a functioning 
market. The important factor was a flexible 
subsidy policy, which could be adapted to suit the 
changing socio-economic, and technological 
framework conditions and which was able to take 
account of the specific requirements of invention, 
innovation and diffusion during the entire 
innovation cycle. The main characteristic of 
Danish policy was and still is the linkage 
between wind energy policy and other policy 
areas, such as environmental and energy policy. 
In particular, these are: 
• the creation of long-term energy plans, 
• the support for R&D to create a 
knowledge base, 
• the early transition from investment subsidies to 
performance-dependent support for diffusion, 
• the financial participation by broad sections 
of the public and 
• the induced commitment to the expansion of 
wind energy on the part of energy suppliers. 
In Germany also, environmental policy 
instruments brought about the emergence of a 
market niche for wind energy use with a 
significant volume, where reliable and profitable 
wind turbines were developed and institutional 
innovation, such as the formation of industrial 
associations and business networks made it 
possible to develop investment models. In 
principle, the support policy in Germany is similar 
©IPTS-JRC -Seville, 1999 
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to that in Denmark. In Germany also, the 
sequence of instruments used took account of the 
various phases of the innovation process (see 
Figure 2). It should nonetheless be pointed out 
that this policy did not follow any strategic plan, 
but rather developed gradually, and was therefore 
able to learn. 
In Great Britain, on the other hand, support for 
market launches under the NFFO (Non Fossil Fuel 
Obligation) began before British companies had 
been able to develop efficient wind technologies 
with the help of R&D subsidies. In consequence, 
British manufacturers were not prepared for 
competition, while self-supporting wind energy 
industries have developed in Denmark and 
Germany. This should be no surprise, when one 
considers that the primary goal of the NFFO 
is to ensure the survival of existing nuclear 
Table 1. 
power stations. The differences between the 
corresponding factors influencing innovation in 
the development and use of wind energy 
technology are listed together in Table 1. This also 
shows the major differences between the 
framework conditions in Denmark, Germany and 
Great Britain, which affected the influence of the 
policy instruments used. 
Increasing pressure on costs, both through the 
type of instruments used (i.e. oriented towards 
returns or .based on tendering procedures) and 
through reductions in subsidies, is leading to 
increased competition in all three countries. 
It is becoming increasingly important for 
manufacturers to draw upon their experience to 
reduce the specific costs of their equipment, in 
order to gain more room for manoeuvre in 
pricing. This is achieved partly through R&D to 
Factors influencing innovation in the wind industry 
Germany Denmark Great Britain 
Framework conditions 
for development 
Technological 
conditions 
Market structure 
Market volume 
Market growth 
Learning curve 
Good engineering 
and craft professions 
increasing 
concentration 
Domestic: high 
Export: low 
Domestic: uncertain 
Export: high 
First mover 
Good craft professions 
increasing 
concentration 
Domestic: medium 
Export: high 
domestic: high (offshore 
Export: high 
First mover 
manufacturing 
industry not 
strongly represented 
Domestic: medium 
Domestic: medium 
Framework conditions 
for use 
Energy system 
Prices 
Risk 
Environmental factors 
centralized 
falling price per kWh 
high exposure 
centralized, in transition 
falling price per kWh 
low exposure 
growing problems with slight problems with 
public acceptance public acceptance 
centralized, in transition 
falling price per kWh 
high exposure 
high problems with 
public acceptance 
w 9 
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As a consequence of 
market pressure, 
generating costs 
per kWh wind power 
have fallen significantly 
in recent years. 
At the same time 
manufacturers have 
consolidated 
In Germany there 
has been a lack 
of agreement on 
how to exploit the 
accumulated store of 
technical solutions in 
realizing environmental 
and energy policy goals 
Figure 2. Regulatory framework in Germany 
Improvements 
in legal and 
administrative 
framework 
Feed-in-law 
BMBF-R&D-Support 
Credit financing 
BMBF-support 
for demostration 
Depreciation 
under tax law 
Federal states 
support 
BMBF-100/250 
MW-Programme 
produce innovation in products and processes. 
There are also attempts to secure returns from 
innovation by being the first on the market and 
achieving a large market share as quickly as 
possible. As a consequence of this market 
pressure, generating costs per kWh wind power 
have fallen significantly in recent years. At the 
same time, the market concentration of German 
and Danish manufacturers has risen markedly. It is 
possiljJs that a global oligopoly of suppliers may 
eventually emerge. 
Despite its improved competitiveness 
compared to fossil fuels, the situation of wind 
energy use in Germany was considerably less 
certain than in Denmark or Great Britain until the 
elections in September 1998. However, it is to be 
expected that the situation in Germany will 
change considerably since there are new efforts to 
support renewable energies over the coming 
years. Up to that point, in contrast to Germany, 
Great Britain's Electricity Act provided a legal 
basis for further expansion of wind energy, albeit 
at a very low level. In Denmark, it was possible to 
construct a broad consensus on further expansion 
of wind energy among the participating actors, i.e. 
energy suppliers, wind farm operators, the state 
and the general public. 
In Germany there has been a lack of 
agreement on how to exploit the accumulated 
store of technical solutions in realizing 
environmental and energy policy goals. In the first 
place, there was considerable resistance to the 
use of wind energy among energy suppliers, who 
wanted to keep specialization benefits and protect 
their own very large capacity. This was expressed 
in capacity planning which takes no account of 
expansion in wind energy. Thus the already 
installed wind energy capacity leads to fuel 
conservation, but capacity effects were scarcely 
realized. There was consequently a great deal of 
uncertainty for both the operators and 
manufacturers of wind technology in Germany as 
to the future development of the domestic market. 
In Great Britain and Denmark, on the other 
hand, the participation of energy suppliers was 
forced through legal measures. Moreover, steps 
have been taken to further decentralize energy 
©IPTS-JRC -Seville, 1999 
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supply. Secondly, in Germany as much as in 
Great Britain, acceptance among affected local 
residents was falling as wind energy achieved 
more market penetration. The response in 
Germany has included looking at options for 
involving residents financially in the operating 
companies, thereby learning from the Danish 
experience with wind co-operatives, in which the 
majority of the population has a stake. Due to the 
structure of the tendering procedure, this would 
appear hard to implement in Great Britain. 
innovation-oriented policies patterns 
It is clear that a pool of technical solutions and 
a niche market can be built up by means of 
innovation-oriented environmental policy. It is 
important firstly that innovation is induced, in 
order to reduce the costs for a technology to a 
competitive level, to overcome the essential 
technical problems and to create the right 
conditions for exploiting past experience. 
Secondly, the necessary institutional framework 
conditions must be created. A decisive factor here 
is an open, flexible policy framework, which uses 
a combination of various instruments and is able 
to adapt both to the specific conditions in each 
phase of the innovation process and to changes in 
the technical and socio-economic framework 
conditions. It is also important for the effects of 
using an instrument to be monitored through 
continuous evaluation. In the wind energy sector, 
an instrument package which makes an attempt to 
trigger a technology leap, with the subsequent 
economic and technological uncertainty and 
unpredictability, has proved not to be necessarily 
advantageous. Instead, a gradual approach 
whereby a new technology is continually 
improved in small steps has proved to be 
effective. 
After building up a store of technologies and a 
market niche, further instruments must be used to 
create a functioning market. Thus, defining the 
future status of renewable energy in the energy 
supply system in Germany now has become a 
crucial task. Also the introduction of the neweco-
tax in Germany could be a turning point if the use 
of wind energy were exempted, which could 
become more profitable for business than 
conventional power station technologies. Both 
measures are characteristic for the success of 
Danish policy. With the introduction of the 
energy and C 0 2 taxes, Denmark achieved a 
partial internalization of the external effects of 
power generation and improved the 
competitiveness of renewable sources. Moreover, 
the long-term national energy plans, similarly to 
Great Britain's Electricity Act, set out concrete 
goals for the expansion of wind energy and other 
renewable energy sources as substitutes for coal-
fired power stations. J5 
w n \°< 
Promoting a 
technology to the 
point where it is able to 
overcome the essential 
technical problems and 
begin to compete 
is a key part of 
creating a pool of 
technical solutions 
and niche market 
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Thinking about EMU and Science 
S t u a r t S c h w a r t z s t e i n , LSE 
Issue: The advent of European Monetary union (EMU) undoubtedly constitutes a major 
economic and political event. Despite considerable attention to EMU, however, what 
effects it will have in a wide range of areas is not at all clear and experts are divided. 
Among those areas like to be affected - at least to some degree - is scientific research 
and technological development, but as wi th many other areas at this t ime one can only 
speculate on the impact that EMU will have on science in Europe. 
Relevance: EMU is not only highly significant, but the success or failure of monetary 
union can have long term effects on the continued integration of Europe at a number of 
levels and on the ability of European science to compete effectively on a global scale. 
E uropean Monetary Union (EMU), which created a single currency in January of this year, is likely to be seen by historians as one of the most important economic 
events in post-war Europe. It is certainly the most 
important event to take place in Europe since the 
collapse of the Soviet Union. But, even as we 
consider its importance, it should be kept in mind 
that the primary impetus for monetary union is 
not economic, but political, and that the tenacity 
to which most European leaders have held to 
plans for EMU - despite considerable trepidation 
and opposition - is more an indicator of the 
importance attached to political integration than 
the conviction that a single currency itself will 
bring significant economic benefits. EMU may 
stem from the political commitments contained in 
the Maastricht Treaty, but will overshadow it. 
Some commentators see EMU as not only of great 
significance politically within Europe, but an 
event that will be a watershed in US-European 
relations. And there are those, like Martin 
Feldstein, former chairman of the Council of 
Economic Advisors to the US President, who 
believe that while extremely important, the effects 
will be negative. In a highly-publicized article of 
November 1997 Feldstein wrote: "if EMU does 
come into existence, it will change the political 
character of Europe in ways that could lead to 
conflicts in Europe and confrontations with the 
United States" (Feldstein, 1997). Just as much of 
the impetus for EMU comes from those who want 
to see an integrated Europe as a counter-balance 
to the US, there are those in the US who fear that 
a more integrated Europe wil l be more 
a competitor than a partner. But there is a 
consensus that even if seen by much of the public 
as an "obscure financial undertaking" it is of great 
significance and cannot be ignored. 
There is much, of course, about the EMU that 
remains to be seen. In the economic sphere, it is 
likely to be in the structural effects - first order, 
second order and other knock-on effects — that 
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But for those 
concerned with science 
and technology 
in Europe, what are 
the likely impacts? 
Within the EU greater 
ease of comparison is 
likely to level out costs. 
Using one currency 
will also make 
administration easier 
within the euro zone 
EMU will have the most impact. By all accounts, 
it will create a strong currency - one that is likely 
to rival the dollar as a reserve currency - and no 
doubt will further integrate those members of the 
European Union who choose to participate.1 One 
might also, reasonably, expect the most careful 
and prudent fiscal management by both 
governments of the eleven states which will 
initially participate in the EMU and concerted 
efforts to make certain that there are no serious 
economic downturns, at least in the first year or 
two of a single currency, when it would be blamed 
(rightly or wrongly) for any that might occur. The 
degree to which high unemployment rates can be 
addressed during this period will also represent a 
serious challenge to member governments; one we 
can expect will be given a high priority. 
But for those concerned with science and 
technology in Europe, what are the likely impacts? 
And for those concerned with cooperation in 
science and technology between the US (and 
Japan, as well as other countries) and European 
Union partners, what can be expected? 
Interestingly — and somewhat surprisingly, given 
the importance of science and technology for 
modern economies — little seems to have been 
written and published on the impacts that EMU 
may have on S & Τ other than those devoted to the 
administrative and software problems that will 
inevitably be raised (at least in the initial period). 
Information that this writer has received from 
various experts and commentators on science 
policy indicates that little attention is being paid 
to what impacts EMU may have on science and 
technology in Europe - on funding, administration 
of R & D or on possible changes to EU approaches 
to support for research and development as a 
result of monetary union. 
There are a few things that are readily apparent. 
First, cost comparisons between countries will be 
considerably easier and will not be subject to the 
distortions of currency fluctuations. Nor, within 
the EMU group, will there be disparities in interest 
rates and thus there will be greater equalization of 
certain costs. Certainly, with one currency in 
which all budgets and costs can be denominated, 
the administration of research (and manufacturing) 
facilities throughout the Euro zone wil l be 
considerably easier and the mobility of researchers 
also made easier by denomination of costs and 
salaries in a single currency. Beyond that, the 
effects are less obvious. 
It may, however, be useful to speculate on 
possible effects of EMU on scientific research at 
least for the short term. In the view of this writer, 
we are likely to see the following: 
• Commitment to the Euro as a strong currency 
by the central bank keeping interest rates as 
high as necessary for strength, but not 
significantly higher than existing rates: this 
may have the effect of discouraging some 
commercial sector investment in research 
facilities, at least in those areas where payoff 
is neither in the short term nor of the high-
risk, high return sort. The impact of interest 
rates on investment wi l l , however, be 
determined not only by interest rates of the 
Euro but those in other major currencies, 
opportunity costs and what long-term 
strategies firms may have. 
• Consolidation of both manufacturing and 
research facilities within the EMU group: This 
may result in greater rationalisation and more 
effective use of resources. It may also -
perhaps more in the short than long term -
result in a decrease in the number of 
laboratories and other research facilities. 
• Greater availability of capital for research: the 
expected euphoria (Europhoria?) over EMU is 
likely to push share prices higher, providing 
firms with capital, at least some of which can 
be expected to be used for research and 
development. (If, for some high-tech firms, 
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they are able to sustain the kinds of high 
price-earnings ratios that some US high-tech 
firms currently enjoy, they will enjoy this 
benefit whatever the interest rates.) 
• Greater impact on research collaboration by 
medium-sized firms than on large ones: for 
large enterprises, the obstacles to 
collaboration have been relatively less 
important and the greater ease of 
collaborating across national borders will 
thus have less impact than on smaller firms 
which may heretofore have been 
discouraged. 
• Increased pressure for standardisation of 
practices, greater conformity to EU-wide 
approaches and greater integration within the 
EU. Greater ease of administration across 
national borders and an increased need for 
European-wide perspectives will drive other 
measures. 
• Rethinking of how the principle of 
"subsidiarity"2 applies to research and 
development, with most likely a strong tilt 
towards more decision-making and more 
efforts on a supranational level. 
• Greater standardization and integration of 
national policies and support for scientific 
research and development. Greater pressure 
for greater standardization of educational 
qualifications to promote the mobility of 
researchers. 
• Pressure for greater harmonisation of tax laws 
and national (and sub-national3) spending 
policies, including but not limited to those 
related to research. 
• Little impact on the Fifth Framework 
Programme : long-debated and fought over, 
EMU is not likely to affect either the decisions 
already made or the administration of the 
Commission's Fifth Framework Programme. 
• To gain competitive advantage within the 
EMU, states and regions may well undertake 
efforts to provide what concessions, tax 
advantages, subsidies and other measures 
possible (to the extent that they can be legally 
permitted under EU agreements, directives 
and regulations) to industry and, particularly, 
those research-intensive high-tech industries 
which are seen as both having a future and as 
not damaging to the local environment. 
• Greater impetus given to the consolidation 
and re-structuring of European defence 
industries across national borders, including 
defence R & D . Efforts to create pan-European 
defence industries able to compete effectively 
with their US counterparts will be given a 
boost. (This may have a negative impact on 
cooperation with the US in some areas of 
defence research.) 
But what of relations in science and 
technology with the US overall? First, this writer 
believes that both competition and cooperation 
wi l l continue to mark US-EU relations in 
this area. The globalization of science, the 
importance of both the US and of EU member 
states in science mean that cooperation is 
inevitable and, indeed, that competition, wil l 
also remain a significant part of the relationship. 
Indeed, with greater consolidation and 
rationalization, European enterprises may well 
be tougher competitors.4 For US firms, the cost 
of contracting for research in EU countries may, 
however, be higher than in the past, if relative to 
the dollar the exchange rate of the Euro is higher 
than that of national currencies now used.5 For 
European firms, a strong Euro may well provide 
an incentive to contract for research or set up 
facilities in the US - which would argue for 
greater cooperation. 
But a stronger and more integrated Europe 
will also mean that demands for conformity to 
American standards will be more easily resisted. 
The terms on which cooperation is based may 
shift somewhat towards European preferences, 
The removal of 
obstacles to 
collaboration across 
national borders 
could favour small 
companies, for 
whom their relative 
importance was greater 
Greater harmonization 
is likely also to create 
greater pressure for 
standardization of 
educational 
qualifications to 
promote the mobility 
of researchers 
The globalization of 
science and the 
importance of both the 
US and of EU member 
states in science mean 
that cooperation is 
inevitable and, indeed, 
that competition, will 
also remain a 
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Better coordinated 
cross border research 
and greater mobility 
for researchers may 
mean more of them 
look for opportunities 
within Europe rather 
than emigrate 
to the US 
standards, terms and conditions - with the 
possible exception of what is done in various 
information technology areas. This will be true 
of cooperation in science and technology, but 
also in other areas as well. For "mega-science" 
or those scientific efforts which are necessarily 
funded in large part by governments and which 
inevitably must be dealt with at a political level, 
one can expect greater influence by Europe. 
The greater ease of administration of research 
facilities across national borders, the lessened 
difficulty in mobility for researchers and the 
greater likelihood that European researchers will 
find and avail themselves of professional 
opportunities within Europe, rather than 
emigrate to the US (as have so many scientists 
in the past), may also create changes in 
the relationship. US and Western European 
enterprises may also compete more strongly for 
researchers from former Warsaw Pact states, 
particularly as the strong attraction of the dollar 
is lessened with a rival reserve currency. 
It is also likely that the political and defence 
relationships of the US and the EU, which will 
have impacts on cooperation in science and 
technology, will change as well. Some change 
has already been brought about by the collapse of 
the Soviet Union and the demise of a military 
threat from the east. There have been a number of 
differences in foreign and defence policy and 
some may say growing resentment of a 
dominating role by the US. (Certainly legislation 
like the Helms-Burton bill and the Iran-Libya 
Sanctions Act have created fears among many 
Europeans that if they do not unite and do not 
themselves constitute a formidable bloc, they will 
be prey to unreasonable extraterritorial demands 
by the US.) If the EMU succeeds, it will bolster 
efforts to create the common European foreign 
and defence policy and, most likely, force changes 
in the relationship with the US. These changes will 
not necessarily be negative, but to maintain the 
relationship as friendly (and allied) will likely 
require changes in attitudes and actions by the US. 
Even as we contemplate changes likely to be 
brought about by EMU, we might also give some 
thought as to what might happen if EMU does 
not succeed(or if as Professor Martin Feldstein 
fears, it gives rise to a variety of conflicts). Even 
with the best of intentions and a good deal of 
political wi l l , one must consider the possibility 
of failure and certainly the possibility of 
increased rather than decreased conflicts within 
Europe must be at least be considered. Failure of 
EMU would, in its trail, no doubt bring both 
disillusionment with the European Union, 
greater reliance on national approaches and 
structures and might well, also, unleash a 
number of centrifugal forces. This would not 
necessarily mean that relations with the US 
would warm commensurately; rather there could 
well be less coherence and less predictability. 
Although some in the US may be apprehensive 
about the advent of EMU, once it is in place US 
interests are more with success than failure - for 
cooperation in science and technology as well 
as relations in general. 
What might also be considered are what 
impacts EMU will have on relations with those 
European states which will not be members of 
the monetary union (or, like the UK, which have 
deferred it). One might ask how EMU will affect 
both relations with states outside the region (like 
the US) and those within, as well as with respect 
to those states which are aspiring to join the 
European Union. 
Conclusion 
Although a good deal remains to be seen 
about EMU and its effects, what is clear is that is 
will be of major significance and will constitute 
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an important step in further integration of Europe 
within the framework of the European Union. 
The impacts on science and technology and the 
conduct of scientific research will undoubtedly 
take some time to be felt, but it is likely that there 
will be noticeable effects. The importance of 
EMU for science should not, however, be 
exaggerated: compared with other developments 
(like the Fifth Framework Programme starting in 
1999) it may well be relatively minor. But for 
Europe overall and for other countries' 
relationships with Europe, monetary union 
and its effects wil l be important issues to 
follow closely. ¡K 
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Notes 
1 - Eleven members of the EU have met the criteria for membership and are committed to entering EMU 
as of January 1999. 
2- As defined by the Treaty on European Union, it means that the EU can act only when it has the 
necessary legal power and that that which is done at an EU level should only be done when an objective 
can be better achieved at a supranational rather than national level. How this is interpreted has been a 
matter of dispute, but greater integration of member states through EMU may well tip the balance further 
towards those who take an "integrationist" approach. 
3- e.g. the German länder. 
4- Airbus and Eurofighter may be the models to be followed in other fields. 
5- Although it may well have minimal effect: One might note that despite the strength of sterling, a 
number of US and Japanese firms have opened, maintained and expanded research facilities in the UK. 
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Consumers increasingly 
demand higher quality 
and greater safety 
from consumer goods. 
This demand is met in a 
variety of ways and on 
a number of levels 
The Consumer Product Safety Database: 
products, risks and expertise 
José Javier Alba Sánchez, Cuy Bordin, Adela Rodriguez, IRMM 
issue: The European Commission has made the tools available to the Member States to 
enable them to ensure safety in internal market for consumer products. However, the 
situation can never be static, and development of specific tools to extend the existing 
range is worthwhile. Among these tools, databases have the advantage of being able to 
store a huge amount of information that can be classified according to real needs. Their 
availability is immediate when they are deployed on the web, where they have the big 
advantage of allowing feedback from the users, thus contributing to their improvement. 
Relevance: Laboratories, companies, consumer associations and services of the 
European Commission have shown an interest in the development of a database that 
collects data about expertise in the field of product safety. The Consumer Product 
Safety database dovetails with these developments and can fruitfully interact with 
other systems in the field. 
Introduction: serving citizens through 
the use of new technologies 
C onsumers increasingly demand higher quality and greater safety from consumer goods. The response to this demand comes from a number of levels: 
governments, industry, specialized groups, 
researchers and other bodies involved in 
consumer protection. 
Each year, a number of events relating to 
consumer protection are held. These include 
conferences, congresses, workshops and fairs. 
The number of different issues tackled in these 
the world of consumer protection. In addition, 
different countries and regions have a multiplicity 
of policies, legal systems, social and cultural 
traditions and institutional contexts. There are 
therefore many approaches to consumer 
protection issues, depending on regional factors. 
Supranational organizations such as the European 
Commission have to face additional problems 
deriving from the heterogeneous nature of 
consumer protection subjects. 
Moving forward within such a complex 
framework requires the adoption of a clear 
strategy. One such strategy is to deal with specific 
aspects of consumer protection individually. The 
events is enormous - a sign of the complexity of European Union, conscious of this reality, is 
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promoting projects serving specific objectives. 
These projects include those set up by the 
following acts: 
• Decisions of the Council of the European 
Union 81/623/EEC, 86/138/EEC, 90/534/EEC, 
93/683/EEC and the Decision of the European 
Parliament and of the Council 3092/94/EC; 
these Decisions introduce a Community 
System of Information on Home and Leisure 
Accidents (EHLASS). 
• Decisions of the Council of the European 
Union 84/133/EEC, 89/45/EEC, 90/352/EEC, 
90/651/EEC and 93/580/EEC; these Decisions 
introduce a Community System for the Rapid 
Exchange of Information on Dangers arising 
from the use of consumer products (CSREID). 
• Council Directive 92/59/EEC on general safety 
of products. 
Having considered the directive on general 
safety of products, the Joint Research Centre and 
the former Consumer Policy Service (now 
Directorate-General XXIV) signed a collaboration 
agreement for the creation of, among other things, 
a data bank on the safety of products. This data 
bank would: 
• Contain a classification of consumer products 
and their potential risks of use excluding food 
products1, live animals and chemicals2 
• Cover institutes, laboratories, research centres 
and test and evaluation facilities with expertise 
in product safety 
• Establish for each facility, its capability, means, 
expertise, specializations, qualified personnel 
and how its expertise may be accessed 
This database was initially designed to 
complement the CSREID (the Community System 
for the Rapid Exchange of Information on Dangers 
arising from the use of consumer products). This 
system works as follows: the official authorities in 
Member States of the European Union notify 
the European Commission when a possibly 
dangerous product appears in the single market of 
the Union by means of the CSREID. When such a 
product is detected, in many cases it must be 
carefully tested in order to confirm its danger to 
potential consumers or users before any measure 
can be taken (e.g. withdrawal of the product from 
the market). The intervention in the single market 
by the relevant authorities can have not only have 
consequences for consumers relating to the 
specific product, possibly jeopardizing the 
freedom of trade within the European Union, but 
may also affect overall commerce between 
Member States (see Figure 1). To avoid these 
unwanted effects, but still provide protection to 
the consumers, it must be clearly determined 
whether the product represents a hazard3 to 
consumers or not. 
The way the database on products, risks and 
experts complements the CSREID is by facilitating 
the task of finding those experts capable of giving 
an independent and reliable diagnosis in any 
field of the analysis (chemical, physical, 
meteorological, standards and regulations, etc.) 
relative to consumer products. If the supposedly 
dangerous product is found to represent a risk to 
consumers, the European Commission can take 
the appropriate measures. 
This database was originally conceived as a 
tool to assist in Directorate-General XXIV (DG 
XXIV) activities, in the event of the introduction 
of a dangerous product into the market. However, 
the current situation, as was explained earlier, 
has suggested an expansion to its use. Namely, 
the opening of the database for access to a fuller 
spectrum of possible users: other directorates 
of the European Commission, the expert 
organizations present in the database, sectors of 
industry, consumer associations, etc. This 
enlargement can be facilitated by the application 
of new technologies to the database (e.g. its 
deployment on the Internet). 
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Figure 1. The complex framework of consumer protection 
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Figure 2. The application of information technologies for the 
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An overview of the application of information 
technologies for the implementation of consumer 
protection policies in the European Union is 
shown in Figure 2. 
Characteristics of the database 
The first pillar of the database is its relational 
aspect (Figure 3). A relational database permits 
the realization of complex query operations 
involving more than one source of information, 
thus allowing optimal exploitation of the stored 
information. 
The entities of the database (or elements 
about which one wants to store information) 
form another important pillar of the database 
structure. Each of these entities has a series of 
attributes, or basic elements of information, such 
as the description of a product, the type of 
analyses that an expert is capable of making, the 
description of a risk, etc. 
In addition to the classifications of products 
and risks, there are lists of keywords for each 
product and risk definition, which allow 
unlimited scope for expansion of data, without 
adding extra work to maintenance tasks. There 
may be hundreds of keywords linked to each 
heading. Therefore, the possibilities for 
expansion are unlimited. 
Finally, modularity is the third pillar on which 
the database is supported. The database has 
been built by assembling units that perform 
specific tasks, so that either its maintenance or 
its enlargement and improvement may be 
made in the most simple and rapid way, and 
without affecting other structures that perform 
different tasks. 
Figure 3. Characteristics of the database on safety of products 
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The database has been 
designed to be 
relational, so as to 
permit complex 
queries involving more 
than one source 
of information 
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The database has 
been given an 
expandable multi-
language support 
capability 
In order to make the 
list of experts as 
complete as possible, 
the initial action was 
to contact the 
corresponding official 
organizations of all the 
countries of the 
European Union, as 
well as consumer 
organizations 
Modularity was an essential part of providing 
the database with one very important option: 
support for multiple languages. As it is 
conceived, the database can offer its information 
in any language within a wide spectrum, among 
which are included all of the official languages 
of the European Union. For practical reasons, its 
development is limited to five languages: 
English, French, Spanish, German and Italian, 
but the possibility of extending this choice of 
languages exists and can be easily activated in 
response to demand. 
The general structure of the database is shown 
in Figure 4, including the sources of data and links 
to external entities. 
Sources of data 
This is one of the most complex points, since it 
involves searching for reliable and stable 
information which is clearly applicable to the 
objectives of the project. The information must also 
obey the heterogeneity of consumer protection 
subjects as explained in the introduction. 
The structure designed for the database allows 
for three entities, or arrangements of data: experts, 
products and risks. 
The data for the 'experts' entity relate to 
institutes and laboratories able to perform 
analyses of consumer goods in any of the possible 
branches. These data refer to location (name of 
the organization, complete address, means of 
location - telephone, fax, e-mail), expert 
personnel in analysis of products and type of 
services that the organization is capable of 
making (for example, chemical analysis of toys). 
In order to make the list of experts as complete 
as possible, the initial action was to contact the 
corresponding official organizations of all the 
countries of the European Union, as well as 
Figure 4. Structure of the database on safety of products 
Unks lo external 
classifications 
200 records Sources ol data 
Consumer associations 
Official bodies 
Experts 
400 records 
Experts in consumer 
product analysis 
Examples of queries 
Experts in analysis of a given product 
Experts in identification of a certain risk 
from a product 
Risks associated to a product and vice-versa 
Risks that an expert is capable to identify 
Others 
Access by header Access by keyword 
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consumer organizations. This round of 
consultations produced a list of about 400 expert 
institutes, with expertise in the analysis of 
consumer products. This survey is periodically 
repeated. Furthermore, the expert organizations 
can communicate by their own initiative any 
changes in the information. 
Regarding the second entity (products) the 
first version of the database was based on the 
Tariff and Statistical Nomenclature (European 
Commission DC XXI). This produced a large 
classification with more than 15,000 definitions of 
products. However, the Tariff and Statistical 
Nomenclature is not specific to the field of 
consumer protection, and thus added complexity 
to the database because of its size whilst offering 
little in terms of precision. This fact motivated the 
search for new sources of data. 
Among the existing classifications of products, 
the International Classification of External Causes 
of Injuries (ICECI, World Health Organization), 
the International Classification of Diseases (ICD-10, 
World Health Organization), and the National 
Electronic Injury Surveillance System (NEISS, US 
Consumer Product Safety Commission) have 
shown themselves to be more consumer oriented 
and less complicated. Nevertheless, they are 
not as complete as the Tariff and Statistical 
Nomenclature and they still do not entirely fit the 
objectives of the database. 
Therefore, the best solution to finding a source 
of data for products was to create an original 
classification of products, fully adapted to our 
needs. This new classification takes into account 
the sources mentioned above, associating their 
advantages and even extending some: reduced 
complexity and unlimited growth capability. 
With respect to the risks, the process of finding 
a source of data has proceeded in parallel to the 
case of products: since none of the studied 
classifications fitted completely the objectives of 
the database, the creation of an original 
classification of risks was decided upon. Certain 
classifications were taken as a reference, among 
those mentioned above (ICD-10, ICECI), together 
with some bibliographical research. The 
Community System for the Rapid Exchange of 
Information on Dangers (CSREID), arising from 
the use of consumer products (European 
Commission DC XXIV) was also carefully taken 
into account. That Community system collects 
real data on consumer goods which could be 
dangerous, together with a definition of the 
danger they represent, and therefore is a very 
valuable reference. 
The classification of risks involves about 200 
risk descriptions. The possibilities for expansion 
here are unlimited because of the use of lists of 
keywords, as explained in the characteristics of 
the database. 
Working methods 
Updating the information and the applied 
technology is essential for the efficiency and 
reliability of the database. To achieve this goal, we 
have applied a method that uses the output of one 
step as the input for the next. This results in a 
cyclical process of continuous improvement (e.g., 
the ordinary maintenance tasks reveal the need 
for a new procedure, then a design process starts, 
which is implemented and then maintained, thus 
closing the cycle) (See Fig. 5). 
To fulfil the criterion of continuous 
improvement, in the first place, the deployment of 
the database on the Internet has been put forward. 
This application will contain interactive elements, 
so that communication with the users can be 
made fast and direct. Feedback from users arising 
out of applying the cyclical maintenance 
The best solution to 
the problem of 
classifying data was to 
create an original 
classification of 
products, fully adapted 
to the project's needs 
The classification 
of risks involves about 
200 risk descriptions. 
The possibilities for 
expansion here are 
unlimited because 
of the use of lists 
of keywords 
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Making the database 
available on the 
Internet would mean 
that feedback from 
users would be rapid 
and direct 
A periodic updating 
process is envisaged, 
involving contacts with 
the organizations that 
serve as a reference for 
the classifications of 
products and risks 
The European 
Commission's 
Fourth Framework 
Programme for 
research has supported 
the development of 
the Consumer Product 
Safety (CPS) Database. 
The database is also in 
line with the theme of 
Fifth Framework 
Programme 
Figure 5. The cycle of continuous improvement 
Design 
Implementation 
Maintenance 
philosophy will be a decisive factor in ensuring 
the validity of the information and tailoring the 
application to users' needs. 
Secondly, the update of the data is not only left 
to those criteria suggested by users, but 
periodically (typically once a year), a survey is 
made between the experts that are present in the 
database. This survey permits updating the 
information as well as searching for new experts. 
Periodic contact is also maintained with the 
organizations that serve as a reference for the 
classifications of products and risks (Directorates-
General of the European Commission, the WHO 
and the CPS Commission in the US) to permit the 
continual updating of the data. 
The principle of continual improvement also 
affects the technology which is applied. The 
renewal and improvement in software and 
hardware, together with the update of the criteria 
for their correct management, are essential points 
in the development of the database. 
Perspectives within the new framework 
programme for research 
consumer-oriented projects has been fully 
assimilated by it. As a result, the database has 
aroused the interest of experts in the analysis of 
consumer products, and also sectors of industry 
and several departments of the European 
Commission involved in consumer protection. 
This fact supports the idea that tools of this kind 
(implementation of policies through the use of 
technology) are valid instruments for the 
achievement of certain policy objectives, 
particularly in the field of consumer protection. 
Equally relevant is the idea of linking tools to 
others of the same kind, thereby increasing 
information retrieval possibilities yet further. For 
example, since the database on products, risks 
and experts stores information linked to 
international classifications of products and risks 
(Tariff and Statistical Nomenclature, ICECI, 
ICD-10 and NEISS), it is feasible to create an 
interface with other databases and electronic 
systems (such as EHLASS, CSREID or the sub-
bases of COST Action 99), which also use these 
classifications. This associative process would 
produce much more complete information in the 
field of consumer protection, and therefore, the 
potential for exploiting the results is very high. 
Besides the initial purpose of the database on The European Commission's Fourth 
products, risks and experts for supporting certain Framework Programme for research has 
Commission activities, the shift towards more supported the development of the Consumer 
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Product Safety (CPS) Database. That Framework 
Programme was highly influenced by the RTD 
provisions introduced in the Treaty on European 
Union and by the Commission's White Paper on 
Growth, Competitiveness and Employment. The 
database is also in line with the theme of Fifth 
Framework Programme (FP5). Protecting 
consumers, benefiting from the information 
society, putting research at the service of the 
citizen and concentrating efforts in specific areas 
to help to solve problems are samples of those 
new themes in which the database fits 
completely. 
In the same vein, the application of the latest 
information technologies to the database will 
facilitate immediate reactions to new needs as 
they arise. The short time of reaction could 
contribute to the self-confidence of consumers 
and entities involved in consumer protection, 
which is a necessary feature of an open society. 
Identifying future needs is a task that must be 
undertaken by researchers and policy makers. 
The CPS database will serve the corresponding 
FP5 objectives, but in addition there are a 
number of possibilities that should be explored. 
For example, the CPS database could help to 
underpin harmonization in the field of consumer 
safety for the new coming members of the 
Union. Furthermore, association and co-
operation with other systems in the same field 
can bring to light unexpected possibilities that 
could be explored, j f 
Keywords 
consumer products, consumer protection policy, dangerous products, databases, experts in analysis of 
consumer products, Information society, risks associated to consumer products, serving the citizen, 
single market, support to community policies 
Notes 
1- Equivalent systems exist in the field of food safety, such as Langual (http://food.ethz.ch/langual/) 
within the frame of COST Action 99 and the Rapid Alert System for Foodstuffs (European Commission, 
DG XXIV). 
2- Equivalent notification procedures exist for pharmaceuticals (Directive 75/319/EEC and 81/851/EEC), 
animal diseases (Directive 82/894/EEC), products of animal origin (Directive 89/662/EEC) and in the 
form of the System for the Rapid Exchange of Information in radiological emergencies (Decision 
87/600/Euratom). 
3- A 'safe product' means any product which, under normal or reasonable foreseeable conditions of 
use, including duration, does not represent any risk or only the minimum risks compatible with the 
product's use (Directive 92/59/EEC art. 2-b). 
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Patent protection for biotechnological 
inventions: incentive for European 
biotech innovators 
Nikolaus Thumm, IPTS 
issue: Protection of biotechnological inventions has been and still ¡s a matter of public 
debate but it is also a recent concern of policy makers. Within Europe an additional task 
is the harmonization of the different national regulations for the protection of 
biotechnological inventions. 
Relevance: Protection of intellectual property is essential for biotechnology firms and 
the debate on what, how and when biotechnological inventions can be protected by 
legal means is continuing. Recent European legislation tried to clarify these issues. How 
this legislation will be implemented and how firms will react to the new legal framework, 
however, remains to be seen. 
introduction 
B iotechnology is one of the leading future technologies and besides computer and information technology a key-technology for the economic development of the 
next millennium. This is revealed with particular 
clarity by the sector's growth rates (tablel ). 
Table 1 . 
The remunerative aspects of intellectual property 
rights have particular significance for biotechnology 
as research and development costs are high but 
copying marketed products is relatively easy. This is 
highlighted, for instance, by the fact that it still takes 
around 12 years to bring a new medicine onto the 
market and average research and development 
costs are over $300 million. Industry will, of course, 
Development of Europe's Biotech industry 
1996 
R&D expenditure +21% 
number of companies 584(+20%) 
employees 17,200(+7%) 
1997 
+20% 
716(+23%) 
27,000(+60%) 
1998 
+27% 
1036(+45%) 
39045(+42%) 
Source: Annual Ernst & Young Reports on the European Biotechnology Industry 
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The high investment 
costs involved and the 
ease of copying the 
results make the 
biotechnology industry 
particularly sensitive 
to the issue of 
intellectual property 
only make this kind of investment if its return is 
protected, and intellectual property rights 
protection, mainly in the form of patents, is the type 
of protection most frequently sought. 
However, the legal framework for patent 
protection, at least in Europe, is still far from 
coherent. National, European (European Patent 
Convention, EPC) and international (Patent 
Convention Treaty, PCT) patent rights exist in 
parallel. The use of the European patent has risen 
tremendously during the last decade and has 
largely eclipsed the number of national patent 
applications. 
Figure 1. European patent applications 
in biotechnology (defined by PCT 
Classes C07G,C12M,N,P,Q,R.S) 
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Source: EPO, ESPACE bulletin 
However, the EPC is still not a system which 
provides a harmonized legal framework for patent 
rights in Europe, the proposal for a community 
patent made in 1989 has still not been adopted 
and one of the main problems for European legal 
patent protection - apart from the high application 
and maintenance costs - is the possibility of 
different interpretations by national laws and 
national courts, which brings with it a high risk of 
legal heterogeneity within Europe. Thus the need 
for a coherent legal framework is evident and the 
recent directive on "legal protection of 
biotechnological inventions" (98/44/EEC) is very 
much along these lines. 
Current issues in protection of 
biotechnological intellectual property 
There is considerable public debate on the 
scope of what is really patentable so far as 
biotechnological inventions are concerned. The 
new European directive on the legal protection of 
biotechnological inventions tries to lay down the 
guideliness for the whole debate. Nevertheless, 
already within normal patent law the 
requirements for patentability of biotechnological 
items is clearly defined. Article 52.1 of the 
European Patent Convention Treaty states that 
patents may be granted for inventions which are 
novel, based on an inventive step and are capable 
of industrial application. Excluded from 
patentability, according to article 53, are 
inventions that are contrary to morality or the 
"public order". However, a decision on this point 
is a value judgement that is based on principles 
outside patent law itself. Article 53 b also specifies 
that animals, plant varieties and breeding 
methodologies are excluded from patentability. 
The new interpretation given by the new directive 
to the patentability criteria (invention, novelty, 
inventive step and industrial application) may 
supersede this exclusion. 
Invention 
Inventions have to be distinguished from mere 
discoveries. Frequently it is perceived that the 
natural existence of a substance, especially in the 
case of genes, means that the item can be 
discovered but not invented. Thus a protein or a 
gene sequence are discovered rather than 
invented. However, legal practice in patenting 
takes industrial applicability into account in order 
to distinguish between discoveries and inventions. 
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In the case of genes, a patenting practice had 
already been established -and this was reaffirmed 
by the new directive- whereby a patent can be 
granted when the gene is isolated and made 
available for practical industrial purposes. Thus 
the definition of what an invention is, as contrasted 
with a mere discovery, depends first of all on 
whether it is technologically applicable. Genetic 
engineering, for example, is regarded as a 
sophisticated form of technical invention. 
Novelty 
An invention is novel as long as it does not 
belong to the "state of the art" in the field. This is 
tested by the previous availability to the public 
(European Patent Convention (EPC) Art 54(2)). 
Novelty is distorted by "everything made available 
to the public by means of a written or oral 
description, by use, or in any other way, before the 
filing date of the European patent application" 
(Article 54(2) EPC). In the view of the European 
Patent Office (EPO) the mere pre-existence of a 
substance is insufficient to contradict the novelty 
criterion (see e.g. the Alpha-interferon case, 
BIOGEN/Alpha interferons EPO Appeal Board 
Decision T301/87, EPO Official Journal OJ EPO 
1990/8, 335). Consequently also the pre-existence 
of genes does not destroy novelty. 
inventive step 
The test for the necessary inventive step is 
based on the idea of the invention's not being 
immediately obvious to an expert familiar with 
the state of the art in the field. Thus it is more a 
question of ingenuity in the individual case of an' 
invention. With respect to the isolation of genes 
the answer to this question is left to a case-by-
case decision by the patent authority. 
Industrial applicability 
Article 57 EPC defines industrial applicability 
for inventions. This could, of course, be a 
problem; especially in the case of the 
identification of the gene sequence, where many 
sequences are identified without the knowledge 
of the exact function and therapeutic value of the 
coded protein. 
The directive on the legal protection of 
biotechnological inventions 
It is now more than ten years since the first 
draft of the directive for the protection of 
biotechnological inventions was rejected by the 
European Parliament. The European Parliament at 
that time had strong concerns about the 
patentability of nucleotide sequences derived 
from human genetic research, but also voiced 
general ethical concerns. Finally, on 12 May 
1998, the European Parliament accepted the 
Commission's latest proposal with 432 votes in 
favour and 78 against (mainly the green party) and 
24 abstentions. 
Basic principles of the new legislation 
Article 3 of the directive extends the general 
prerequisites of patentability to biological 
material (defined in Article 2) and claims that such 
material is in general patentable even if it 
previously occurred in nature, providing, the 
industrial application is clearly specified in the 
application. Article 4 tries to ensure consistency 
with Article 53 b EPC by excluding plant and 
animal varieties and essential biological 
procedures for the breeding of plants and animals 
from patentability. Exceptions however, and this is 
important, are possible for cases that are not 
technically confined to a particular plant or 
animal variety. 
Article 5, 1 also establishes the principle of 
non-patentability for the human body and parts of 
it. Whereas in part two of the same Article 
exceptions are defined for isolated elements of the 
human body that are produced "by means of a 
technical process", and explicitly including 
X 
29 
Part of the difficulty 
with patenting 
biological material is 
that it often resembles 
a discovery more than 
an invention. This is 
overcome by applying 
the principle of 
technical applicability 
Genes may also be 
argued to exist already, 
and therefore lack 
novelty. However, the 
novelty criterion applies 
to the pre-existence of 
a description of the 
thing in the public 
domain, not the 
thing Itself 
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In the case of 
patenting material 
originating from the 
human body, the 
traditional ethical 
grounds for refusing a 
patent have been 
extended to explicitly 
cover issues such 
as cloning, etc 
Despite the length 
of time the directive 
has been under 
discussion the debate 
surrounding it 
still continues 
sequences of genes. The article also gives a 
clearer position on what parts of the human body 
can be regarded as a patentable inventions and 
not mere discoveries. Just as in existing patent 
law, ethical and public policy objections are 
grounds for exclusion. In particular these criteria 
mean the following are excluded: 
• procedures for human reproductive cloning 
• processes for modifying the germ line genetic 
identity of human beings 
• methods in which human embryos are used 
• processes for modifying the genetic identity of 
animals which are likely to cause them 
suffering without any substantial medical 
benefit to man or animal and also animals 
resulting from such processes 
Article 11 provides farmers with the privilege 
of utilizing offspring from transgenic stocks 
without paying any royalties (the so called 
farmers' privilege). 
Reactions to the directive 
Already the adoption of the new 
biotechnology directive is very controversial, 
though this is not surprising given the fact that it 
took nearly a decade to get it through the 
legislative process. The date for transposition 
into the national law of the Member States is July 
2000. Nevertheless, it continues to be debated 
just as fiercely as before its adoption, as shown 
by the most recent nullity suit (October 1998) by 
the Dutch government against the European 
directive (98/44/EEC), for reasons of non-
compliance with the principle of subsidiarity, 
violation of fundamental human rights and 
contradiction with international treaties. Press 
reaction to the directive ranges from vehement 
rejection to enthusiastic support. Clearly, the 
doubts concerning the directive are still very 
much alive and many people have yet to be 
convinced of its benefits. 
Are patents still an adequate protection tool? 
Serious concern now exists as to how far the 
patent system remains an adequate tool for 
protecting intellectual property. Indeed, the 
dramatic changes in the structure of the industry 
during recent decades may also mean that a 
dramatic change in the intellectual property rights 
system is needed. The original intention of 
rewarding invention so as to provide an incentive 
through guaranteeing economic benefits for 
research and development has become simplistic 
and does not match the requirements of new 
industries like biotechnology or those related to the 
information society. "The intellectual property rights 
system was developed for an industrial era, while 
now complex issues of a post-industrial period are at 
stake... the time is ripe for a wholesale reassessment 
of traditional approaches to the definition and 
protection of intellectual property" (Pirages 1996, 
page 273). Today's brainpower industries and their 
complexity pose new challenges to the intellectual 
property rights system. Furthermore, nowadays it is 
less and less the case that innovations are driven by 
breakthroughs than by the routine exploitation of 
existing technologies. This gives rise to the 
possibility of innovations consisting of the 
concentration of all known characteristics plus one 
new one. This kind of "recombination model" 
(Foray 1992, page 9) of invention clearly means 
that the availability and the access to information is 
gaining in relative importance. An intellectual 
property right system is also a political tool as it 
establishes a balance between individual rights and 
responsibility to society "Society isn't going to let 
someone have a monopoly on the cure for cancer" 
(Lester C. Thurow, 1997 page 98). Political value 
judgements of this type, however, differ a lot 
between countries according to their degree of 
economic development. Developing countries 
tend to emphasize responsibility to the public 
over individual rights of creators, whereas 
in industrialized countries it is usually the other 
way round. 
m m m m m 
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"Patenting life" 
An issue which has always been problematic is 
whether genetic material or information taken 
from human beings and plant and animal varieties 
can be patented. According to the new directive 
for the first time elements isolated from the human 
body by means of technical process are 
patentable. Opponents fear that human beings, 
plants and animals might be reduced to a mere 
genetic resource. 
Since 1977 over 7500 patent applications on 
human genes, from plants and animals have 
been submitted to the European Patent Office. 
The new directive is therefore only formalizing 
what has been legal practice for a long time 
anyway. The new directive explicitly excludes 
procedures for cloning human beings or human 
germ line interventions and also the use of 
human embryos for industrial purposes. 
Scientists fear royalties will be an obstacle to 
science. There are also fears are that farmers 
might become more dependent on large firms 
which hold the gene patents on genetically 
altered plants or animals. 
The industry's reaction to the directive, 
however, has generally been positive given that 
the patenability of biological material has been 
confirmed by Article 6. Nevertheless the issue of 
plant variety and transgenic plants is unresolved 
and the expansion of ethical issues and the 
farmer's privilege is disturbing biotechnology 
firms. From the industry's point of view, any 
weakening of the draft would put Europe at a ' 
further disadvantage and shift the focus of 
research in biotechnology further towards the 
USA and Japan. The harmonization of existing 
national laws on biotechnological patents by the 
directive is encouraging the invention of new 
medicines, which could improve life and health 
of millions of patients by increasing investment 
in research and development. 
Ethical concerns 
According to the legal criteria for patentability 
there are generally speaking no restrictions to the 
patentability of biotechnological inventions. 
Nevertheless, there are some major ethical 
concerns on this subject. The main ethical 
criticism is based on worries that somehow 'life' 
itself is being patented in conjunction with a 
moral view that living animals should never be 
reduced to the status of an object of invention. A 
famous case is the decision of the European Patent 
Office on the so-called Onco Mouse, where a 
patent was claimed for a genetically altered 
mouse by Harvard University. In this decision a 
patent was granted for a transgenic animal. The 
fact that the mouse in question does not occur in 
nature made possible the application for patent 
protection. The underlying argument against 
patent protection of living beings, however, is that 
animals should not be used as mere tools for 
human ends and, in particular, that they should 
not be caused to suffer. The Examination division 
of the European Patent Office justified the 
granting of a patent on the basis of its judgement 
that the likely benefits for cancer research 
outweighed the ethical concerns. This decision 
set the precedent for a utilitarian approach in 
which possible negative consequences are 
justified by the invention's usefulness to mankind. 
Advocates of the new legislation counter 
ethical concerns by pointing out that "patenting 
life" per se is a meaningless notion as patent law 
does not allow the patenting of abstractions. 
Normal application of patent law already 
excludes the following: 
• human beings 
• body organs, limbs, body fluids, and any other 
known part of the human body 
• nucleotide sequences elucidated by human 
genetic research and other molecules 
identified by such research in the human body 
in the their natural state 
\ 
There is some doubt as 
to whether a patent 
system designed for an 
industrial age can really 
be adapted to meet 
the needs of sectors 
such biotechnology or 
information 
technologies 
To some extent the 
directive really only 
formalizes a trend 
towards patenting 
biological material that 
was already underway 
One ethical objection is 
based on the view that 
living animals should 
never be reduced to 
the status of an object 
of invention 
However, precedent 
exists for granting a 
patent on a living 
organism when 
sufficient benefit to 
mankind may be 
expected to be derived 
from it 
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The 'global justice' 
objection fears that 
powerful players in the 
wealthy North will 
exploit the biodiversity 
of the South to 
create a new kind 
of colonialism 
Experience from 
the USA demonstrates 
how important 
the patenting 
environment is for the 
development of 
the biotechnology 
industry. For 
biotechnology firms 
patents may often 
be a prerequisite 
to obtaining 
venture capital 
A patent cannot be granted on the ownership 
of "life". Living organisms can only be patented if 
they differ significantly from naturally occurring 
ones. Moreover, patenting material originating 
from living organisms should not be confused 
with the emotive idea of patenting life. DNA is not 
life, as human beings cannot be reconstructed 
from the sum of human genes. For the evaluation 
of patenting from an ethical point of view, it 
makes a big difference whether genetic alterations 
are allowed for freedom of science or whether 
they are part of an economic premium system, as 
in the case of the patent system. 
Biodiversity and global justice 
Most research is done in the Northern 
Hemisphere, but broadest species variety is found 
in the Southern Hemisphere, which has a greater 
concentration of poorer countries. Western world 
economies gain huge benefit from owning plants 
in impoverished southern countries (See for 
example, Goodman, Walsh, 1997 and the story of 
taxol or "The European Patent Directive: License 
to plunder" http://www.grain.org/publications/ 
reports/plunder.htm) by establishing a sort of bio-
piracy of the genetic resources of the Southern 
hemisphere. An example of this is Madagascar's 
rose periwinkle plant which was used to develop 
anticancer drugs, and other medicines with a 
great worldwide market success, but which never 
returned any financial benefit to Madagascar (The 
World Bank 1998 p. 35). 
This and other examples show that at least a 
minimum level of responsibility towards 
developing countries is required of the actors 
involved. Patenting of genes could mean the 
beginning of an unequal distribution of genetic 
resources between underdeveloped countries and 
industrial nations, amounting to a kind of new 
colonialism by biotech firms. In addition, 
countries in the South might be forced to uphold 
patents obtained by foreign companies on their 
own biodiversity and on the associated 
knowledge of their indigenous peoples and local 
communities, perhaps even endangering 
biodiversity. On the other hand, biotechnology 
research can also contribute to providing the 
world as a whole with a stable food supply. 
Against this backdrop value judgements seem 
unavoidable. 
The new directive as a "competitive 
advantage"? 
Obviously there is a need for a coherent 
European legal framework for the protection of 
biotechnological inventions. Different legal 
regulations in different European countries may 
lead to trade problems within the European 
internal market and industries might hesitate to 
invest in R&D or shift their research base in 
biotechnology to the USA and Japan. In the 
biotechnology field patents can be seen to be 
effective as an incentive to research and 
development (see e.g. Mazzoleni, Nelson 1998). 
For biotechnology firms patents may even be a 
prerequisite to obtaining venture capital 
(Ballantine et al. p. 48). Industry has therefore 
welcomed the new directive since an appropriate 
intellectual property structure is a crucial factor 
influencing a company's decision to invest in, and 
to use, biotechnology. Experience from the USA 
demonstrates how important the patenting 
environment is for the development of the 
biotechnology industry. The real future 
effectiveness of the new directive and whether it 
might foster competitive advantage for Europe 
depends very much depend on its practical 
implementation by the member states during the 
next two years. 
Conclusion 
Further research has to investigate how far the 
directive will affect the behaviour of firms in order 
to evaluate the relevance of the new legal 
M m m m m 
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framework as a factor of European competitiveness 
and how firms will make use of the legislation in 
practice. One specific line of investigation should 
look at the management practices of IPR in Europe 
and also compare them with those of its main 
competitors, the United States and Japan. 
The enormous future responsibility of the 
whole issue should not be underestimated. This 
is even more striking given the relatively low 
public awareness of biotechnology in Europe. 
The lesson to be drawn from the debate so far is 
that the intermingling of economic factors and 
value judgements will make it hard to reach 
definitive conclusions. A lot depends on how 
the directive is implemented at the level of 
the Member States and the subsequent 
interpretations given it by the courts. J j 
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Transatlantic investments and 
human capital formation: the case 
of biotech firms 
Oliver Wolf, Jens Hemmelskamp, Ineke Maisch, Per Sørup, IPTS 
issue: The launch of young, High Tech start-up companies in Europe is partly a result of 
the efforts of European policies to create a new generation of competitive companies. 
A special focus has been placed on information technologies and the life sciences. This 
European effort has been accompanied by a growing interaction between European and 
US firms, mainly through the setting up of strategic alliances or other forms of co-
operation. Additionally, more and more venture capital, mainly from the US, is flowing 
into European start-up companies in the life sciences sector as part of a two way flow 
across the Atlantic. 
Relevance: One of the issues raised by these capital flows is that of their impact on know-
how and human capital. 
e have taken the example of the life 
science sector given the fact that it is 
a sector which is undergoing rapid 
economic and scientific development 
stimulated by large amounts of EC-funds, in order 
to analyse the relationship between US-investors 
and European start-ups. Furthermore, a very 
lively trans-Atlantic economic activity has 
emerged. This indicates that if there were indeed 
a drain of European know-how and human 
capital, it would be possible to track the impacts 
on know-how in this sector accurately. 
The investigation was carried out in two 
steps: Firstly we selected a representative sample 
of firms which had received funding through the 
European Commission in life sciences related 
projects. We then traced the market behaviour of 
these firms, focusing on their relationship with 
US firms and investors. 
European Commission funding for 
life-sciences companies 
In this first step companies were identified 
which participate(d) in one or more of the life 
science related programmes set up by DG XII. 
Project partners included research institutes, 
universities and private firms. 
In order to reduce the total 1575 projects 
down to a manageable number for analysis, a 
limited sample was generated using the search-
term tool in the Cordis database. The search terms 
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Table 1. 
Selected funding programs of the EC (DC Xll) 
in the life science sector since 1988 
Programme 
Biomed I 
Biomed II 
Biomed I 
Biotech II 
Bridge 
Eclair 
TOTAL 
Total amount 
(mECU) 
151 
374 
186 
595.5 
100 
80 
1486.5 
Period 
1991-1994 
1994-1998 
1992-1994 
1994-1998 
1990-1994 
1988-1993 
Number of projects 
274 
650 
161 
351 
97 
42 
1575 
Source: Cordis Database 
used were "biotechnology industry" and, in a 
subsequent step, "industrial". The idea behind this 
procedure was that it is not necessary to take in all 
the projects with industrial participation but to 
obtain a sample of projects which would be small 
enough to work with but large enough to deliver 
useful information. 
The investigation was restricted to companies 
from the United Kingdom, France and Germany, 
as these are the countries where the highest rate of 
new start-ups in the Life Sciences sector can be 
found at the moment. 
The final sample contained 177 projects in 
which 121 companies participated. 
Table 2. 
Market performance of the companies 
identified 
Having identified this sample of 121 companies 
which have received EC-funding in the field of life 
sciences, we looked at their performance during 
and after the funding phase. Our aim was to 
analyse the interaction between these firms and 
US investors. 
Although the sample is not big enough to give 
a solid statistical basis, as a first approximation it 
was clear that some start-up companies which 
have taken or are taking part in EC research 
projects, were bought by US-companies (-7,5%, 
see Table 2). Some of the compan ies in the sample 
had been founded by US-investors, others were 
Ownership of companies participating in EC-life science projects 
(Sample not statistically representative) 
Location of company owners 
Owned by US-investors 
Owned by EU-investors 
No information availablel 
Total no. of analysed companies 
Location of EC-supported companies 
within the sample 
UK 
3 
16 
5 
24 
France 
3 
21 
32 
56 
Germany 
3 
32 
6 
41 
Total 
9 
69 
43 
121 
Source: Cordis Database, Recombinant Capital homepage, l i terature, interviews 
\ 3 5 Y 
% 
A small percentage of 
the companies in the 
sample had been 
founded by US-
investors, others were 
taken over during, 
or after, receiving 
EC-ffunding 
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Taking into account 
other forms of co-
operation (joint 
ventures, licensing, 
mergers etc.) it turns 
out that nearly all of 
the companies are 
involved in one or 
more strategic 
relationships with 
international partners 
US researchers have 
detected considerable 
penetration of the 
US knowledge 
base by European 
biotechnology 
businesses 
taken over during, or after, receiving EC-funding. 
An example of this is provided by the company 
AgriSense. AgriSense took part in the ECLAIR 
project: "The development of environmentally 
safe pest control systems for European olives" 
(1990-1994) and was taken over by the American 
firm BioSys in 1993 - during the funding period 
(Biocontrol, 1997). 
In another case, the French fine chemicals 
producer Sipsy was already a subsidiary of an 
American company when it started in the project 
"Microbial production of native and recombinant 
tailor-made enzymes for fine-chemical produc-
tion" (1996-1999) (Sipsy, 1998). Furthermore it 
can be seen in Table 2 that 69 of the observed 
companies are property of European investors. In 
43 cases no information was available on 
ownership. 
The whole picture - strategic alliances 
on a global level 
Looking only at acquisitions does not provide 
the whole picture. Taking into account other 
forms of co-operations (joint ventures, licensing, 
mergers etc.) it turns out that nearly all of the 
companies -are involved in one or more strategic 
relationships with international partners. These 
co-operations are summarized under the general 
Table 3. 
term, "alliances". Recombinant Capital, a 
research institute analysing the alliances within 
the biotechnology sector, identified 31 different 
types of co-operation between firms 
(Recombinant Capital, 1998) The whole spectrum 
goes from acquisitions and mergers to joint 
development agreements and shared marketing 
activities. 
Although most of these co-operations are 
temporary, the main goal of the alliance is to 
obtain access to new markets and new 
technologies, and the reduction of risk and costs 
for the participating companies. 
The most important motivation for cooperation 
therefore seems to be the further development of 
technologies and business activities in new areas 
European firms - the reverse trend 
One fact stands out, namely that the formation 
of alliances is not only initiated by US firms, 
rather, European firms are also active in this area. 
A look at three large biotech firms from the 
sample shows the number of inter-firm alliances 
among them since 1990 (see Table 3). A 
comparison between European and US Biotech 
firms shows that intercontinental cooperation is 
not exclusively sought by large US firms. 
Number of inter-firm alliances (since 1990) 
Europe 
US 
Company 
Rhone-Poulenc (F) 
Schering (D) 
Zeneca (UK) 
Amgen 
Pfizer 
Pharmacia 
No. of global inter-firm alliances 
93 
89 
39 
35 
78 
89 
Source: Recombinant Capital Homepage, h t tp : / /www.recap.com 
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Figure 1. Shares of venture capital 
1996 
US Funds 
' / - " " ^ ^ 
European ,/ \ 
Funds ƒ - J 
<2% r L ^ ^ I 4 V 
k 
H tocai 
/ Funds 
ψ 71% 
1997 
US Funds / \ 
34% / 
\ V \ 
European 
Funds 
17% 
Λ local 
1 Funds 
1 49% 
Source: Interviews with EVCA and BVCA 
It is worth noting in this context that US 
researchers have investigated if there is a drain of 
know-how from the US to Europe: "The large 
European-based multinationals in chemicals and 
pharmaceuticals, in pursuit of the necessary 
knowledge and skills in biotechnology, have 
through arrangements of one sort or another 
widely penetrated the American knowledge 
base." This implies in the authors opinion "a 
massive 'technology transfer' from the US to 
Europe" (Sharp, 1996). 
Venture Capital 
While the impressive development of 
biotechnological companies in the US in the 
early 90s was fed by considerable flows of 
venture capital, this was not the case in Europe. 
This 'lack of European venture capital' was often' 
interpreted as a 'lack of confidence' in young 
European biotechnology companies. 
This situation has significantly changed 
during the last two years, encouraging sufficient 
venture capital through private European 
investment funds and by various EU and 
Member State investment programmes. 
In addition, a growing interest by various US 
investors can be observed. As interviews with 
the European Venture Capital Association 
(EVCA), the British Venture Capital Association 
(BVCA) and with one of the German Bio-Regio 
administrators show, about 33% of the available 
venture capital in Europe comes from US 
sources. This means that the share of US venture 
capital invested in the EU has doubled during 
the past year (see Figure 1). 
The interviewees stated that European firms 
often look for funding sources in the US and not 
the other way round. The success rate shows, 
among other things, the increasing 
professionality of these young companies. 
Additionally, some European firms are setting up 
offices in the US, but this is often merely a 
formality to go public on NASDAQ. The main 
activities of these firms remain in their home 
countries. 
Bearing in mind that venture capital is invested 
with the aim of obtaining high returns, these 
investments indicate international recognition 
of the growing competitiveness of European 
biotech-firms. 
% 37 
X 
% 
European 
biotechnology 
companies were initially 
hampered by a lack 
of venture capital. 
Although this 
situation has 
improved, a large 
(and increasing) 
amount comes 
from the US 
The flows of 
knowledge and capital 
in the biotechnology 
sector seem to be 
moving in both 
directions across 
the Atlantic 
The fact that so many 
European companies 
look to the US for 
finance may well point 
to the existence of a 
bottleneck in European 
capital markets 
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Conclusions 
• Looking at the selected sample of companies it 
can be stated that in a very limited number of 
cases, European start-up companies, which 
had received EC funding for research, were 
later acquired by US companies. 
• The analysis has also shown that the traditional 
acquisition of companies is only a small part of 
a broad variety of different forms of alliances 
(licensing, joint ventures, mergers etc.) Taking 
this into account, a large number of European 
technology companies have a US partner, 
which may have indirect access to knowledge 
built up with EU funding. 
• However, this movement of knowledge and 
capital is taking place in both directions. 
Surprisingly, European companies are at least 
as active in aligning themselves in the US 
market as the US companies are in Europe. 
What lessons can be learnt? 
• The high technology life sciences sector finds 
itself in a state of rapid change, suggesting an 
initial consolidation phase. These alliances 
(also between global competitors) form part of 
a common process. 
• The intensive activity of US companies in 
Europe indicates the rapidly growing 
attractiveness of European high tech firms. This 
is underlined by the increasing amount of US 
venture capital, currently flowing into Europe. 
The main goal of these investments seems to 
be to participate in the growing success of 
young European companies, in a way similar 
to the European firms' efforts to earn dividends 
from the success of their US partners. 
• The rapid flow of knowledge and capital 
demonstrates that this industry segment is 
knowledge-based and, therefore, largely 
independent of geographical factors. 
Europe on the right track 
One implication which emerges is the need to 
establish an attractive financial environment for 
high technology start-up companies. The fact that 
a lot of young companies look for funding in the 
US may well point to the existence of a bottleneck 
in Europe regarding capital availability. First steps 
in the right direction have already been taken, as 
the First Conference of the Biotechnology and 
Finance Forum showed. This event, organized by 
DC XII and the European Association of Securities 
Dealers (EASD), took place in Brussels on 12 and 
13 May 1998 and aimed at linking the 
biotechnological and the financial sphere in 
Europe closer together, j f 
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A B O U T T H E I P T S 
The IPTS is one of the eight institutes of the Joint Research Centre of the EU Commission. Its remit 
is the observation and follow-up of technological change in its broadest sense, in order to 
understand better its links with economic and social change. The Institute carries out and co­
ordinates research to improve our understanding of the impact of new technologies, and their 
relationship to their socio-economic context. 
The purpose of this work is to support the decision-maker in the management of change pivotally 
anchored on S/T developments. In this endeavour IPTS enjoys a dual advantage: being a part of the 
Commission IPTS shares EU goals and priorities; on the other hand it cherishes its research institute 
neutrality and distance from the intricacies of actual policy-making. This combination allows the 
IPTS to build bridges betwen EU undertakings, contributing to and co-ordinating the creation of 
common knowledge bases at the disposal of all stake-holders. Though the work of the IPTS is 
mainly addressed to the Commission, it also works with decision-makers in the European 
Parliament, and agencies and institutions in the Member States. 
The Institute's main activities, defined in close cooperation with the decision-maker are: 
1. Technology Watch. This activity aims to alert European decision-makers to the social, economic 
and political consequences of major technological issues and trends. This is achieved through the 
European Science and Technology Observatory (ESTO), a European-wide network of nationally 
based organisations. The IPTS is the central node of ESTO, co-ordinating technology watch 'joint 
ventures' with the aim of better understanding technological change. 
2. Technology, employment & competitiveness. Given the significance of these issues for Europe 
and the EU institutions, the technology-employment-competitiveness relationship is the driving 
force behind all IPTS activities, focusing analysis on the potential of promising technologies for job 
creation, economic growth and social welfare. Such analyses may be linked to specific 
technologies, technological sectors, or cross-sectoral issues and themes. 
3. Support for policy-making. The IPTS also undertakes work to supports both Commission services 
and other EU institutions in response to specific requests, usually as a direct contribution to 
decision-making and/or policy implementation. These tasks are fully integrated with, and take full 
advantage of on-going Technology Watch activities. 
As well as collaborating directly with policy-makers in order to obtain first-hand understanding of 
their concerns, the IPTS draws upon sector actors' knowledge and promotes dialogue between 
them, whilst working in close co-operation with the scientific community so as to ensure technical 
accuracy. In addition to its flagship IPTS Report, the work of the IPTS is also presented in occasional 
prospective notes, a series of dossiers, synthesis reports and working papers. 
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The IPTS Report is published in the first week of every month, except for the months of January and August. It is edited in English 
and is currently available at a price of 50 EURO per year in four languages: English, French, German and Spanish. 
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The European Science and Technology Observatory Network (ESTO): 
IPTS - JRC - European Commission 
W.T.C., Isla de la Cartuja s/n, E-41092, Sevilla, Spain 
tel.: +34-95-448 82 97; fax: +34-95-448 82 93; e-mail: ipts_secr@jrc.es 
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ADIT - Agence pour la Diffusion de l'Information Technologique - F 
CEST - Centre for Exploitation of Science and Technology - UK 
COTEC - Fundación para la Innovación Tecnológica - E 
DTU - University of Denmark, Unit of Technology Assessment - DK 
ENEA - Directorate Studies and Strategies - I 
INETTI - Instituto Nacional de Engenharia e Technologic Industrial - Ρ 
ITAS - Institut für Technikfolgenabschätzung und Systemanalyse - D 
NUTEK - Department of Technology Policy Studies - S 
OST - Observatoire des Sciences et des Techniques - F 
SPRU - Science Policy Research Unit - UK 
TNO - Centre for Technology and Policy Studies - NL 
VDI-TZ - Technology Centre Future Technologies Division - D 
VITO - Flemish Institute for Technology Research - Β 
VTT - Group for Technology Studies - FIN 
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